Government-Owned Inventions; Availability for Licensing, 51376-51378 [2011-21155]
Download as PDF
<![CDATA[
mstockstill on DSK4VPTVN1PROD with NOTICES
51376
Federal Register / Vol. 76, No. 160 / Thursday, August 18, 2011 / Notices
section 1111 of the Public Health
Service Act, codified at 42 U.S.C. 300b–
10, also provides advice and
recommendations concerning grants and
projects authorized under section 1109
of the Public Health Service Act (42
U.S.C. 300b–8).
Agenda: The meeting will include a
review and reflection of the previous 24
meetings and a look forward. The
agenda will include topics related to the
past, present, and future work of the
Committee, including: (1) A
presentation of the previous, current
and future endeavors of the External
Review Workgroup’s activities; (2) an
update from the Evidence Evaluation
and Methods workgroup’s progress on
developing the Decision Process Tree;
(3) review of previous reports,
workgroups and publications from the
Committee and next steps for public
health genetics; and (4) discussion and
presentations on the previous and
continued work and reports of the
Advisory Committee’s subcommittees
on laboratory standards and procedures,
follow-up and treatment, and education
and training. Proposed agenda items are
subject to change as priorities dictate.
You can locate the Agenda, Committee
Roster and Charter, presentations, and
meeting materials at the home page of
the Advisory Committee’s Web site at
https://www.hrsa.gov/
heritabledisorderscommittee/.
Public Comments: This meeting will
include an extended public comment
period during the morning session on
September 22, 2011. Members of the
public can submit written comments
and/or present oral comments during
the public comment period of the
meeting. Those individuals who want to
make oral comments are requested to
register online by Tuesday, September
20, 2011, at https://altarum.cvent.com/
event/SACHDNC092011. Requests
should contain the name, address,
telephone number, and any professional
or business affiliation of the person
desiring to make an oral comment.
Groups having similar interests are
requested to combine their comments
and present them through a single
representative. Written comments
should be e-mailed no later than
Tuesday, September 20, 2011 for
consideration. Oral and written public
comment will be included in the
transcripts of the meeting and will be
posted to the committee’s Web site.
Written comments should contain the
name, address, telephone number, and
any professional or business affiliation
of the author. Submit written comments
to Maureen Ball, Meetings Coordinator,
Conference and Meetings Management,
Altarum Institute, 1200 18th Street,
VerDate Mar<15>2010
16:04 Aug 17, 2011
Jkt 223001
NW., Suite 700, Washington, DC 20036,
telephone: 202 828–5100; fax: 202 785–
3083, or e-mail:
conferences@altarum.org.
Contact Person: Anyone interested in
obtaining other relevant information
should write or contact Alaina M.
Harris, Maternal and Child Health
Bureau, Health Resources and Services
Administration, Room 18A–19,
Parklawn Building, 5600 Fishers Lane,
Rockville, Maryland 20857, Telephone
(301) 443–0721, aharris@hrsa.gov. More
information on the Advisory Committee
is available at https://mchb.hrsa.gov/
heritabledisorderscommittee.
Dated: August 12, 2011.
Reva Harris,
Acting Director, Division of Policy and
Information Coordination.
[FR Doc. 2011–21092 Filed 8–17–11; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUMMARY:
Quantitative Measurement of
Syndesmophytes in Ankylosing
Spondylitis Using Computed
Tomography (CT)
Description of Technology:
Syndesmophyte (abnormal bone) growth
in the spine is a hallmark of Ankylosing
Spondylitis, a type of inflammatory
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
arthritis. Syndesmophyte growth is
currently monitored using semiquantitative scoring of radiographs, but
radiographs consider only a small part
of the vertebra, and the method is
subject to reader error. Because
syndesmophytes grow slowly,
radiographs also lack sensitivity. The
invention provides a method to measure
syndesmophytes using data from
computed tomography scans of the
lumbar spine. It provides computer
algorithm that fully quantitates
syndesmophyte volumes in threedimension space. This method allows
precise and accurate measurement of
the presence and rate of growth of
syndesmophytes over time, which for
the first time will permit testing of
whether any treatments can slow the
progression of this type of spinal
arthritis.
Potential Commercial Applications:
• The method would be useful for
clinical trials of drugs against
Syndesmophyte growth.
• Because of the improved precision,
achieving statistical significance in
assessing the efficacy of a drug would
require smaller samples.
Competitive Advantages:
• The present method is more
automated than existing methods.
• The method is more precise and
sensitive than existing methods, thus
providing more reliable statistical
analysis and improved planning in
treatment regimen.
Development Stage: In vivo data
available (human).
Inventors: Sovira Tan (NIAMS), et al.
Publication: Tan S, Yao J, Ward MM,
Yao L, Summers RM. Computer aided
evaluation of ankylosing spondylitis
using high-resolution CT. IEEE Trans
Med Imaging 2008 Sep;27(9):1252–1267.
[PMID 18779065].
Intellectual Property: HHS Reference
No. E–167–2011/0—Software. Patent
protection is not being pursued for this
technology.
Licensing Contact: Michael
Shmilovich, Esq.; 301–435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Arthritis and
Musculoskeletal and Skin Diseases is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate or commercialize this
technology. For collaboration
opportunities, please contact Brian W.
Bailey, Ph.D. at bbailey@mail.nih.gov.
E:\FR\FM\18AUN1.SGM
18AUN1
Federal Register / Vol. 76, No. 160 / Thursday, August 18, 2011 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
An Automated Method for Precise
Measurement of Vertebral Body Height
and Intervertebral Disk Height Using
Computed Tomography
Description of Technology: Vertebral
fractures due to osteoporosis result in
loss of vertebral height. Degenerative
disk disease in the spine results in loss
of disk height. Currently, radiography
and magnetic resonance imaging are
used to assess vertebral and disk height,
and measurements are done manually.
The present invention offers improved
method to measure vertebral and disk
heights. The invention provides
computer algorithm that substantially
automates the task, and uses computed
tomography. The advantage of
computed tomography over radiography
is that of 3D imaging over 2D imaging.
Computed tomography’s advantage over
MRI is better image resolution. The
combination of automation and superior
imaging capability makes the method
substantially more precise than previous
ones. This allows better detection of
changes in vertebral height and disk
height over time, and thus aids in the
planning of appropriate medical
treatment in cases associated with the
loss of vertebral or disk heights, such as
in osteoporosis for example.
Potential Commercial Applications:
• The method would be useful for
clinical trials of drugs for osteoporosis.
• Because of the improved precision,
achieving statistical significance in
assessing the efficacy of a drug would
require smaller samples.
Competitive Advantages:
• The present method is semiautomated.
• The method is more precise and
sensitive than existing methods, thus
providing more reliable statistical
analysis and improved planning in
treatment regimen.
Development Stage: In vivo data
available (human).
Inventors: Sovira Tan (NIAMS), et al.
Intellectual Property: HHS Reference
No. E–166–2011/0—Software. Patent
protection is not being pursued for this
technology.
Licensing Contact: Michael
Shmilovich, Esq.; 301–435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Arthritis and
Musculoskeletal and Skin Diseases is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate or commercialize this
technology. For collaboration
opportunities, please contact Brian W.
Bailey, Ph.D. at bbailey@mail.nih.gov.
VerDate Mar<15>2010
16:04 Aug 17, 2011
Jkt 223001
Monoclonal Antibodies Against
Poliovirus
Description of Technology: Early
work by Hammond et al. showed
gamma globulin to be effective for the
prevention of poliomyelitis. Therefore,
passive immunotherapy could be
another way to treat chronic excretors.
Even though prior attempts to use
intravenous immunoglobulin (IVIG) and
breast milk were unsuccessful, there is
reason to think that higher doses of
antipoliovirus antibodies could result in
complete clearance of poliovirus from
chronically infected individuals. Six
poliovirus-neutralizing MAbs were
recovered from a combinatorial Fab
phage display library constructed from
bone marrow-derived lymphocytes of
immunized chimpanzees. The six MAbs
neutralized vaccine strains and virulent
strains of poliovirus. Five MAbs were
serotype specific, while one MAb crossneutralized serotypes 1 and 2. Both
serotype 2-specific antibodies
recognized antigenic site 1. No escape
mutants to serotype 3-specific MAbs
could be generated. The administration
of a serotype 1-specific MAb to
transgenic mice susceptible to
poliovirus at a dose of 5 μg/mouse
completely protected them from
paralysis after challenge with a lethal
dose of wild-type poliovirus. Moreover,
MAb injection 6 or 12 h after virus
infection provided significant
protection. This application claims the
antibodies described above and methods
for their use.
Potential Commercial Applications:
• Prophylaxis/therapeutic for
poliovirus.
• Post-exposure emergency
prophylaxis of poliovirus.
Competitive Advantages:
• No humanization required.
• Highly potent neutralizing
antibodies.
• Biological materials available.
Development Stage:
• Pre-clinical.
• In vitro data available.
• In vivo data available (animal).
Inventors: Zhaochun Chen, Robert H.
Purcell, Konstantin Chumakov (NIAID).
Publication: Chen Z, et al.
Chimpanzee-human monoclonal
antibodies for treatment of chronic
poliovirus excretors and emergency
postexposure prophylaxis. J Virol. 2011
May;85(9):4354–4362. [PMID:
21345966].
Intellectual Property: HHS Reference
No. E–076–2011/0—U.S. Provisional
Application No. 61/443,915 filed 17 Feb
2011.
Licensing Contact: Peter Soukas, J.D.;
301–435–4646; soukasp@mail.nih.gov.
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
51377
Methods of Treating Giardiasis Using
FDA-Approved Compounds
Description of Technology: This
technology includes a group of at least
twenty-nine, diverse, commercially
available compounds that are newly
identified for activity against Giardia
lamblia parasites. At least six of the
candidate compounds, Bortezomib,
Decitabine, Hydroxocobalamin,
Amlexanox, Idarubicin, and Auranofin
have preexisting FDA approval for
human use for other (non-Giardia)
conditions. Another three compounds,
Fumagillin, Nitarsone and Carbadox
have preexisting approval for veterinary
use for non-Giardia conditions.
Additional active compounds identified
include: Acivicin, Riboflavin butyrate,
BTO–1, GW9662, Dinitroph-dfgp,
Deserpidine, Tetramethylthiuram
disulsulfide, Disulfiram, Mitoxantrone,
Ecteinascidin 743, 17allyaminogeldanamycin, Carboquone
and Nocodazole. The anti-Giardial
activity of these compounds presents a
cost saving opportunity for the rapid
development of new, better tolerated
treatments for the most prevalent
human intestinal parasite infection in
the United States and the world.
Potential Commercial Applications:
• Treatment of Giardia in humans.
• Treatment of Giardia in animals—
dogs and cats.
Competitive Advantages: These
compounds have currently been
approved for human and veterinary uses
of other indications which provides an
opportunity to greatly reduce risk and
pre-market investments both in terms of
time and costs associated with
development and regulatory approval
for new Giardia applications including
the drug resistant Giardiasis.
Development Stage:
• Early-stage.
• Pre-clinical.
• In vitro data available.
Inventors:
• Wei Zheng, Catherine Chen, Juan J.
Marugan, Noel T. Southall, Christopher
P. Austin (NHGRI).
• Osnat Hertzberg, Luidmila
Kulakova, Andrey Galkin (Institute for
Bioscience & Biotechnology Research,
University of Maryland).
Publication: Chen CZ, et al. Highthroughput Giardia lamblia viability
assay using bioluminescent ATP content
measurements. Antimicrob Agents
Chemother. 2011 Feb;55(2):667–675.
[PMID 21078930].
Intellectual Property: HHS Reference
No. E–211–2010/1—U.S. Provisional
Application No. 61/411,509 filed 09
Nov 2010.
Licensing Contact: Tedd Fenn; 301–
435–5031; Tedd.Fenn@nih.gov.
E:\FR\FM\18AUN1.SGM
18AUN1
51378
Federal Register / Vol. 76, No. 160 / Thursday, August 18, 2011 / Notices
Collaborative Research Opportunity:
The NHGRI is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize Novel Compounds for
Treatment of Giardiasis. For
collaboration opportunities, please
contact Claire Driscoll, NHGRI, at
cdriscol@mail.nih.gov.
Dated: August 12, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2011–21155 Filed 8–17–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Alcohol Abuse
and Alcoholism; Amended Notice of
Meeting
Notice is hereby given of a meeting of
the National Advisory Council on
Alcohol Abuse and Alcoholism,
September 12, 2011, 3:30 p.m. to 5:30
p.m., September 13, 2011, 9 a.m. to 1
p.m., National Institutes of Health,
Building 1, 1 Center Drive, Wilson Hall,
Bethesda, MD 20892 which was
published in the Federal Register on
June 29, 2011, 76FRN2011–16858.
The meeting time has changed on
September 12, 2011 from 2:45 p.m. to
5:30 p.m. The location of the meeting
will remain the same.
Dated: August 11, 2011.
Anna P. Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–21126 Filed 8–17–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
mstockstill on DSK4VPTVN1PROD with NOTICES
National Institute on Deafness and
Other Communication Disorders;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
VerDate Mar<15>2010
16:04 Aug 17, 2011
Jkt 223001
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Deafness and Other Communication
Disorders Special Emphasis Panel, P50
Review.
Date: September 27, 2011.
Time: 3 p.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6120
Executive Blvd., Rockville, MD 20852,
(Telephone Conference Call).
Contact Person: Christine A. Livingston,
PhD, Scientific Review Officer, Division of
Extramural Activities, National Institutes of
Health/NIDCD, 6120 Executive Blvd.—MSC
7180, Bethesda, MD 20892, (301) 496–8683,
livingsc@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.173, Biological Research
Related to Deafness and Communicative
Disorders, National Institutes of Health, HHS)
Dated: August 12, 2011.
Anna P. Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
Rm. 11A48, Bethesda, MD 20892, 301–435–
2455, john.czajkowski@nih.gov.
This notice is being published less than 15
days prior to the meeting due to scheduling
conflicts.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page:
deainfo.nci.nih.gov/advisory/bsa.htm, where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
[FR Doc. 2011–21150 Filed 8–17–11; 8:45 am]
Dated: August 12, 2011.
Anna P. Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
[FR Doc. 2011–21146 Filed 8–17–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Cancer Institute Board of
Scientific Advisors.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: National Cancer
Institute Board of Scientific Advisors, caBIG
Oversight Ad hoc Subcommittee.
Date: August 25, 2011.
Time: 11 a.m. to 1 p.m.
Agenda: New Business, caBIG Initiatives
and Oversight Interaction.
Place: National Institutes of Health, 6116
Executive Boulevard, 8th Floor, Rm. 8018,
Rockville, MD 20852, (Telephone Conference
Call).
Contact Person: John Czajkowski, MPA,
Deputy Director for Management, Office of
the Director, National Cancer Institute,
National Institutes of Health, 31 Center Drive,
PO 00000
Frm 00036
Fmt 4703
Sfmt 9990
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Cancer
Advisory Board, September 13, 2011, 9
a.m. to September 13, 2011, 5 p.m.,
National Institutes of Health National
Institutes of Health, Building 31, 31
Center Drive, Conference Room 10,
Bethesda, MD 20892 which was
published in the Federal Register on
August 10, 2011, 76 FR 49493.
This notice is amended to add the
National Cancer Advisory Board Ad hoc
Subcommittee on Global Cancer
Research meeting. The meeting will
convene on September 12, 2011 from
6:30 to 8:30 p.m. in the Diplomat/
Ambassador room at the Bethesda
Regency Hyatt, One Metro Center,
Bethesda, MD 20814.
Dated: August 12, 2011.
Anna P. Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–21137 Filed 8–17–11; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\18AUN1.SGM
18AUN1
]]>Agencies
[Federal Register Volume 76, Number 160 (Thursday, August 18, 2011)]
[Notices]
[Pages 51376-51378]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-21155]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Quantitative Measurement of Syndesmophytes in Ankylosing Spondylitis
Using Computed Tomography (CT)
Description of Technology: Syndesmophyte (abnormal bone) growth in
the spine is a hallmark of Ankylosing Spondylitis, a type of
inflammatory arthritis. Syndesmophyte growth is currently monitored
using semi-quantitative scoring of radiographs, but radiographs
consider only a small part of the vertebra, and the method is subject
to reader error. Because syndesmophytes grow slowly, radiographs also
lack sensitivity. The invention provides a method to measure
syndesmophytes using data from computed tomography scans of the lumbar
spine. It provides computer algorithm that fully quantitates
syndesmophyte volumes in three-dimension space. This method allows
precise and accurate measurement of the presence and rate of growth of
syndesmophytes over time, which for the first time will permit testing
of whether any treatments can slow the progression of this type of
spinal arthritis.
Potential Commercial Applications:
The method would be useful for clinical trials of drugs
against Syndesmophyte growth.
Because of the improved precision, achieving statistical
significance in assessing the efficacy of a drug would require smaller
samples.
Competitive Advantages:
The present method is more automated than existing
methods.
The method is more precise and sensitive than existing
methods, thus providing more reliable statistical analysis and improved
planning in treatment regimen.
Development Stage: In vivo data available (human).
Inventors: Sovira Tan (NIAMS), et al.
Publication: Tan S, Yao J, Ward MM, Yao L, Summers RM. Computer
aided evaluation of ankylosing spondylitis using high-resolution CT.
IEEE Trans Med Imaging 2008 Sep;27(9):1252-1267. [PMID 18779065].
Intellectual Property: HHS Reference No. E-167-2011/0--Software.
Patent protection is not being pursued for this technology.
Licensing Contact: Michael Shmilovich, Esq.; 301-435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The National Institute of
Arthritis and Musculoskeletal and Skin Diseases is seeking statements
of capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize this technology.
For collaboration opportunities, please contact Brian W. Bailey, Ph.D.
at bbailey@mail.nih.gov.
[[Page 51377]]
An Automated Method for Precise Measurement of Vertebral Body Height
and Intervertebral Disk Height Using Computed Tomography
Description of Technology: Vertebral fractures due to osteoporosis
result in loss of vertebral height. Degenerative disk disease in the
spine results in loss of disk height. Currently, radiography and
magnetic resonance imaging are used to assess vertebral and disk
height, and measurements are done manually. The present invention
offers improved method to measure vertebral and disk heights. The
invention provides computer algorithm that substantially automates the
task, and uses computed tomography. The advantage of computed
tomography over radiography is that of 3D imaging over 2D imaging.
Computed tomography's advantage over MRI is better image resolution.
The combination of automation and superior imaging capability makes the
method substantially more precise than previous ones. This allows
better detection of changes in vertebral height and disk height over
time, and thus aids in the planning of appropriate medical treatment in
cases associated with the loss of vertebral or disk heights, such as in
osteoporosis for example.
Potential Commercial Applications:
The method would be useful for clinical trials of drugs
for osteoporosis.
Because of the improved precision, achieving statistical
significance in assessing the efficacy of a drug would require smaller
samples.
Competitive Advantages:
The present method is semi-automated.
The method is more precise and sensitive than existing
methods, thus providing more reliable statistical analysis and improved
planning in treatment regimen.
Development Stage: In vivo data available (human).
Inventors: Sovira Tan (NIAMS), et al.
Intellectual Property: HHS Reference No. E-166-2011/0--Software.
Patent protection is not being pursued for this technology.
Licensing Contact: Michael Shmilovich, Esq.; 301-435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The National Institute of
Arthritis and Musculoskeletal and Skin Diseases is seeking statements
of capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize this technology.
For collaboration opportunities, please contact Brian W. Bailey, Ph.D.
at bbailey@mail.nih.gov.
Monoclonal Antibodies Against Poliovirus
Description of Technology: Early work by Hammond et al. showed
gamma globulin to be effective for the prevention of poliomyelitis.
Therefore, passive immunotherapy could be another way to treat chronic
excretors. Even though prior attempts to use intravenous immunoglobulin
(IVIG) and breast milk were unsuccessful, there is reason to think that
higher doses of antipoliovirus antibodies could result in complete
clearance of poliovirus from chronically infected individuals. Six
poliovirus-neutralizing MAbs were recovered from a combinatorial Fab
phage display library constructed from bone marrow-derived lymphocytes
of immunized chimpanzees. The six MAbs neutralized vaccine strains and
virulent strains of poliovirus. Five MAbs were serotype specific, while
one MAb cross-neutralized serotypes 1 and 2. Both serotype 2-specific
antibodies recognized antigenic site 1. No escape mutants to serotype
3-specific MAbs could be generated. The administration of a serotype 1-
specific MAb to transgenic mice susceptible to poliovirus at a dose of
5 [mu]g/mouse completely protected them from paralysis after challenge
with a lethal dose of wild-type poliovirus. Moreover, MAb injection 6
or 12 h after virus infection provided significant protection. This
application claims the antibodies described above and methods for their
use.
Potential Commercial Applications:
Prophylaxis/therapeutic for poliovirus.
Post-exposure emergency prophylaxis of poliovirus.
Competitive Advantages:
No humanization required.
Highly potent neutralizing antibodies.
Biological materials available.
Development Stage:
Pre-clinical.
In vitro data available.
In vivo data available (animal).
Inventors: Zhaochun Chen, Robert H. Purcell, Konstantin Chumakov
(NIAID).
Publication: Chen Z, et al. Chimpanzee-human monoclonal antibodies
for treatment of chronic poliovirus excretors and emergency
postexposure prophylaxis. J Virol. 2011 May;85(9):4354-4362. [PMID:
21345966].
Intellectual Property: HHS Reference No. E-076-2011/0--U.S.
Provisional Application No. 61/443,915 filed 17 Feb 2011.
Licensing Contact: Peter Soukas, J.D.; 301-435-4646;
soukasp@mail.nih.gov.
Methods of Treating Giardiasis Using FDA-Approved Compounds
Description of Technology: This technology includes a group of at
least twenty-nine, diverse, commercially available compounds that are
newly identified for activity against Giardia lamblia parasites. At
least six of the candidate compounds, Bortezomib, Decitabine,
Hydroxocobalamin, Amlexanox, Idarubicin, and Auranofin have preexisting
FDA approval for human use for other (non-Giardia) conditions. Another
three compounds, Fumagillin, Nitarsone and Carbadox have preexisting
approval for veterinary use for non-Giardia conditions. Additional
active compounds identified include: Acivicin, Riboflavin butyrate,
BTO-1, GW9662, Dinitroph-dfgp, Deserpidine, Tetramethylthiuram
disulsulfide, Disulfiram, Mitoxantrone, Ecteinascidin 743, 17-
allyaminogeldanamycin, Carboquone and Nocodazole. The anti-Giardial
activity of these compounds presents a cost saving opportunity for the
rapid development of new, better tolerated treatments for the most
prevalent human intestinal parasite infection in the United States and
the world.
Potential Commercial Applications:
Treatment of Giardia in humans.
Treatment of Giardia in animals--dogs and cats.
Competitive Advantages: These compounds have currently been
approved for human and veterinary uses of other indications which
provides an opportunity to greatly reduce risk and pre-market
investments both in terms of time and costs associated with development
and regulatory approval for new Giardia applications including the drug
resistant Giardiasis.
Development Stage:
Early-stage.
Pre-clinical.
In vitro data available.
Inventors:
Wei Zheng, Catherine Chen, Juan J. Marugan, Noel T.
Southall, Christopher P. Austin (NHGRI).
Osnat Hertzberg, Luidmila Kulakova, Andrey Galkin
(Institute for Bioscience & Biotechnology Research, University of
Maryland).
Publication: Chen CZ, et al. High-throughput Giardia lamblia
viability assay using bioluminescent ATP content measurements.
Antimicrob Agents Chemother. 2011 Feb;55(2):667-675. [PMID 21078930].
Intellectual Property: HHS Reference No. E-211-2010/1--U.S.
Provisional Application No. 61/411,509 filed 09 Nov 2010.
Licensing Contact: Tedd Fenn; 301-435-5031; Tedd.Fenn@nih.gov.
[[Page 51378]]
Collaborative Research Opportunity: The NHGRI is seeking statements
of capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize Novel Compounds
for Treatment of Giardiasis. For collaboration opportunities, please
contact Claire Driscoll, NHGRI, at cdriscol@mail.nih.gov.
Dated: August 12, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2011-21155 Filed 8-17-11; 8:45 am]
BILLING CODE 4140-01-P
